, Volume 37, Issue 6, pp 657–663

Arrhythmogenic right ventricular cardiomyopathy

What is needed for a cure?
  • G. Thiene
  • I. Rigato
  • K. Pilichou
  • D. Corrado
  • C. Basso
Main topic


There have been major advances in recent years in the clinical setting of arrhythmogenic right ventricular cardiomyopathy, including new diagnostic criteria, a changing spectrum of the disease with even left dominant forms, the role of cardiac magnetic resonance and electroanatomic mapping, the expanding use of genetic screening and the existence of overlapping phenotypes. Moreover, early diagnosis at pre-participation screening with sports disqualification and risk stratification for the indication of ICD have been shown to be life-saving. In addition to traditional therapies targeting arrhythmias and congestive heart failure, an effective treatment of the disease could be based on the discovery of the molecular mechanisms involved in the pathobiology of the disease in order to block the onset and progression of cell death.


Arrhythmogenic right ventricular cardiomyopathy Pathogenesis Sudden death Therapy 

Arrhythmogene rechtsventrikuläre Kardiomyopathie

Was ist für die Therapie wichtig?


Diagnostik und Management der arrhythmogenen rechtsventrikulären Kardiomyopathie (ARVC) wurden in den letzten Jahren erheblich verbessert. Dies betrifft die Präzisierung diagnostischer Kriterien, die Erweiterung des Krankheitsspektrums auf überwiegend linksventrikuläre Formen, die das klinische Bild dominieren können, den diagnostischen Beitrag der kardialen Magnetresonanztomograpie und des elektroanatomischen Mappings, die Umsetzung des genetischen Screenings in die Praxis und die Beobachtung, dass der klinische Phänotyp Überlappungen zu anderen Kardiomyopathieformen aufweisen kann. Die Früherkennung durch Screeninguntersuchung vor Wettkämpfen mit Ausschluss des Sportlers vom Wettkampfsport und ggf. prophylaktischer Defibrillatorbehandlung (ICD), je nach individueller Risikoeinschätzung, ist nachweislich lebensrettend. Neben der traditionellen Behandlung der Arrhythmie und der Herzinsuffizienz sollte eine zukünftige Behandlung auf diejenigen molekularen Mechanismen in der Pathobiologie der ARVC zielen, die die Auslösung oder Progression des myokardialen Zelltods verursachen.


Arrhythmogene rechtsventrikuläre Kardiomyopathie Pathogenese Plötzlicher Herztod Therapie 


  1. 1.
    Thiene G, Corrado D, Basso C (2007) Arrhythmogenic right ventricular cardiomyopathy/dysplasia. Orphanet J Rare Dis 2:45PubMedCrossRefGoogle Scholar
  2. 2.
    Basso C, Corrado D, Marcus FI et al (2009) Arrhythmogenic right ventricular cardiomyopathy. Lancet 373:1289–1300PubMedCrossRefGoogle Scholar
  3. 3.
    Basso C, Bauce B, Corrado D, Thiene G (2011) Pathophysiology of arrhythmogenic cardiomyopathy. Nat Rev Cardiol 9:223–233PubMedCrossRefGoogle Scholar
  4. 4.
    Marcus FI, McKenna WJ, Sherrill D et al (2010) Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation 121:1533–1541PubMedCrossRefGoogle Scholar
  5. 5.
    Bauce B, Basso C, Rampazzo A et al (2005) Clinical profile of four families with arrhythmogenic right ventricular cardiomyopathy caused by dominant desmoplakin mutations. Eur Heart J 26:1666–1675PubMedCrossRefGoogle Scholar
  6. 6.
    Sen-Chowdhry S, Syrris P, Prasad SK et al (2008) Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll Cardiol 52:2175–2187PubMedCrossRefGoogle Scholar
  7. 7.
    Sen-Chowdhry S, Syrris P, Ward D et al (2007) Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation 115:1710–1720PubMedCrossRefGoogle Scholar
  8. 8.
    Basso C, Corrado D, Thiene G (2010) Arrhythmogenic right ventricular cardiomyopathy: what’s in a name? From a congenital defect (dysplasia) to a genetically determined cardiomyopathy (dystrophy). Am J Cardiol 106:275–277PubMedCrossRefGoogle Scholar
  9. 9.
    Corrado D, Basso C, Thiene G (2011) Arrhythmogenic cardiomyopathy. Cardiac Electrophysiology Clinics, Elsevier, New YorkGoogle Scholar
  10. 10.
    Perazzolo Marra M, Leoni L, Bauce B et al (2012) Imaging study of ventricular scar in arrhythmogenic right ventricular cardiomyopathy: comparison of 3D standard electroanatomical voltage mapping and contrast-enhanced cardiac magnetic resonance. Circ Arrhythm Electrophysiol 5:91–100CrossRefGoogle Scholar
  11. 11.
    Corrado D, Basso C, Leoni L et al (2005) Three-dimensional electroanatomic voltage mapping increases accuracy of diagnosing arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 111:3042–3050PubMedCrossRefGoogle Scholar
  12. 12.
    Garcia FC, Bazan V, Zado ES et al (2009) Epicardial substrate and outcome with epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 120:366–375PubMedCrossRefGoogle Scholar
  13. 13.
    Corrado D, Basso C, Leoni L et al (2008) Three-dimensional electroanatomical voltage mapping and histologic evaluation of myocardial substrate in right ventricular outflow tract tachycardia. J Am Coll Cardiol 51:731–739PubMedCrossRefGoogle Scholar
  14. 14.
    Vasaiwala SC, Finn C, Delpriore J et al (2009) Prospective study of cardiac sarcoid mimicking arrhythmogenic right ventricular dysplasia. J Cardiovasc Electrophysiol 20:473–476PubMedCrossRefGoogle Scholar
  15. 15.
    Corrado D, Leoni L, Link MS et al (2003) Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 108:3084–3091PubMedCrossRefGoogle Scholar
  16. 16.
    Corrado D, Calkins H, Link M et al (2010) Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation 122:1144–1152PubMedCrossRefGoogle Scholar
  17. 17.
    Thiene G, Nava A, Corrado D et al (1988) Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med 318:129–133PubMedCrossRefGoogle Scholar
  18. 18.
    Corrado D, Basso C, Rizzoli G et al (2003) Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol 42:1959–1963PubMedCrossRefGoogle Scholar
  19. 19.
    Corrado D, Basso C, Pavei A et al (2006) Trends in sudden cardiovascular death in young competitive athletes after implementation of a pre-participation screening program. JAMA 296:1593–1601PubMedCrossRefGoogle Scholar
  20. 20.
    Bauce B, Nava A, Beffagna G et al (2010) Multiple mutations in desmosomal proteins encoding genes in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart Rhythm 7:22–29PubMedCrossRefGoogle Scholar
  21. 21.
    Xu T, Yang Z, Vatta M et al (2010) Multidisciplinary Study of Right Ventricular Dysplasia Investigators. Compound and digenic heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 55:587–597PubMedCrossRefGoogle Scholar
  22. 22.
    Asimaki A, Tandri H, Huang H et al (2009) A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. N Engl J Med 360:1075–1084PubMedCrossRefGoogle Scholar
  23. 23.
    Kaplan SR, Gard JJ, Protonotarios N et al (2004) Remodeling of myocyte gap junctions in arrhythmogenic right ventricular cardiomyopathy due to a deletion in plakoglobin (Naxos disease). Heart Rhythm 1:3–11PubMedCrossRefGoogle Scholar
  24. 24.
    Kaplan SR, Gard JJ, Carvajal-Huerta L et al (2004) Structural and molecular pathology of the heart in Carvajal syndrome. Cardiovasc Pathol 13:26–32PubMedCrossRefGoogle Scholar
  25. 25.
    Rizzo S, Lodder EM, Verkerk AO et al (2012) Intercalated disc abnormalities, reduced na+ current density and conduction slowing in desmoglein-2 mutant mice prior to cardiomyopathic changes. Cardiovasc Res 95_409–418Google Scholar
  26. 26.
    Garcia-Gras E, Lombardi R, Giocondo MJ et al (2006) Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. J Clin Invest 116:2012–2021PubMedCrossRefGoogle Scholar
  27. 27.
    Basso C, Thiene G, Corrado D et al (1996) Arrhythmogenic right ventricular cardiomyopathy: dysplasia, dystrophy or myocarditis? Circulation 94:983–991PubMedCrossRefGoogle Scholar
  28. 28.
    Pilichou K, Remme CA, Basso C et al (2009) Myocyte necrosis underlies progressive myocardial dystrophy in mouse dsg2-related arrhythmogenic right ventricular cardiomyopathy. J Exp Med 206:1787–1802PubMedCrossRefGoogle Scholar
  29. 29.
    Migliore F, Zorzi A, Michieli P et al (2012) Prevalence of cardiomyopathy in Italian asymptomatic children with electrocardiographic T-wave inversion at preparticipation screening. Circulation 125:529–538PubMedCrossRefGoogle Scholar
  30. 30.
    Corrado D, Basso C, Thiene G (2012) Sudden cardiac death in athletes: what is the role of screening? Curr Opin Cardiol 27:41–48PubMedCrossRefGoogle Scholar
  31. 31.
    Thiene G, Carturan E, Corrado D, Basso C (2010) Prevention of sudden cardiac death in the young and in athletes: dream or reality? Cardiovasc Pathol 19:207–217PubMedCrossRefGoogle Scholar
  32. 32.
    Wichter T, Paul M, Eckardt L et al (2005) Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD? Herz 30:91–101PubMedCrossRefGoogle Scholar
  33. 33.
    Dalal D, Jain R, Tandri H et al (2007) Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 50:432–440PubMedCrossRefGoogle Scholar
  34. 34.
    Thiene G, Angelini A, Basso C et al (1998) Novel heart diseases requiring transplantation. Adv Clin Path 2:65–73PubMedGoogle Scholar
  35. 35.
    Wlodarska EK, Wozniak O, Konka M et al (2006) Thromboembolic complications in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Europace 8:596–600PubMedCrossRefGoogle Scholar
  36. 36.
    Chachques JC, Argyriadis PG, Fontaine G et al (2003) Right ventricular cardiomyoplasty: 10-year follow-up. Ann Thorac Surg 75:1464–1468PubMedCrossRefGoogle Scholar
  37. 37.
    Kirchhof P, Fabritz L, Zwiener M et al (2006) Age- and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation 114:1799–1806PubMedCrossRefGoogle Scholar
  38. 38.
    Fabritz L, Hoogendijk MG, Scicluna BP et al (2011) Load-reducing therapy prevents development of arrhythmogenic right ventricular cardiomyopathy in plakoglobin-deficient mice. J Am Coll Cardiol 57:740–750PubMedCrossRefGoogle Scholar
  39. 39.
    Charron P, Arad M, Arbustini E et al (2010) Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 31:2715–2726PubMedCrossRefGoogle Scholar
  40. 40.
    Charron P, Héron D, Gargiulo M et al (2004) Prenatal molecular diagnosis in hypertrophic cardiomyopathy: report of the first case. Prenat Diagn 24:701–703PubMedCrossRefGoogle Scholar
  41. 41.
    Kuliev A, Pomerantseva E, Polling D et al (2012) PGD for inherited cardiac diseases. Reprod Biomed Online 24:443–453PubMedCrossRefGoogle Scholar
  42. 42.
    Bushby K, Lochmüller H, Lynn S, Straub V (2009) Interventions for muscular dystrophy: molecular medicines entering the clinic. Lancet 374:1849–1856PubMedCrossRefGoogle Scholar

Copyright information

© Urban & Vogel, Muenchen 2012

Authors and Affiliations

  • G. Thiene
    • 1
  • I. Rigato
    • 1
  • K. Pilichou
    • 1
  • D. Corrado
    • 1
  • C. Basso
    • 1
  1. 1.Department of Cardiac, Thoracic and Vascular SciencesUniversity of PaduaPaduaItaly

Personalised recommendations